Enanta pharmaceuticals, inc.ENTA.US Overview

US StockHealthcare

(No presentation for ENTA)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

ENTA Overall Performance

ENTA AI Analysis & Strategy

ENTA Recent Performance

1.83%

Enanta pharmaceuticals, inc.

0.81%

Avg of Sector

-1.14%

S&P500

ENTA PowerScanner

ENTA Key Information

ENTA Valuation Metrics

ENTA Earnings Table

ENTA Profile

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.